Evidence map›Paper›PMID 35079628›Full record

ArticleBioengineering & translational medicine2022

Biophysical targeting of high-risk cerebral aneurysms.

Mark Epshtein, Moran Levi, Afif M Kraitem, Hikaia Zidan, Robert M King, Meinrad Gawaz, Matthew J Gounis, Netanel Korin

Open access · goldAbstract read
In one paragraph

Article in Bioengineering & translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Cerebral Aneurysm: Filling the Gap Between Pathophysiology and Nanocarriers.International journal of molecular sciences · 2024
    Review
  5. Article
  6. Review
  7. Biophysical targeting of high-risk cerebral aneurysms.Bioengineering & translational medicine · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Mark EpshteinDepartment of Biomedical Engineering Technion Israel Institute of Technology Technion City, Haifa Israel.
Moran LeviDepartment of Biomedical Engineering Technion Israel Institute of Technology Technion City, Haifa Israel.
Afif M KraitemDepartment of Radiology, New England Center for Stroke Research University of Massachusetts Medical School Worcester Massachusetts USA.
Hikaia ZidanDepartment of Biomedical Engineering Technion Israel Institute of Technology Technion City, Haifa Israel.
Robert M KingDepartment of Radiology, New England Center for Stroke Research University of Massachusetts Medical School Worcester Massachusetts USA.
Meinrad GawazDepartment of Cardiology and Angiology University Hospital Tübingen, Eberhard Karls Universität Tübingen Tübingen Germany.
Matthew J GounisDepartment of Radiology, New England Center for Stroke Research University of Massachusetts Medical School Worcester Massachusetts USA.
Netanel KorinDepartment of Biomedical Engineering Technion Israel Institute of Technology Technion City, Haifa Israel.ORCID https://orcid.org/0000-0001-7244-889X
Technion – Israel Institute of Technology · ILUniversity of Massachusetts Chan Medical School · USUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Localized delivery of diagnostic/therapeutic agents to cerebral aneurysms, lesions in brain arteries, may offer a new treatment paradigm. Since aneurysm rupture leading to subarachnoid hemorrhage is a devastating medical emergency with high mortality, the ability to noninvasively diagnose high-risk aneurysms is of paramount importance. Moreover, treatment of unruptured aneurysms with invasive surgery or minimally invasive neurointerventional surgery poses relatively high risk and there is presently no medical treatment of aneurysms. Here, leveraging the endogenous biophysical properties of brain aneurysms, we develop particulate carriers designed to localize in aneurysm low-shear flows as well as to adhere to a diseased vessel wall, a known characteristic of high-risk aneurysms. We first show, in an in vitro model, flow guided targeting to aneurysms using micron-sized (2 μm) particles, that exhibited enhanced targeting (>7 folds) to the aneurysm cavity while smaller nanoparticles (200 nm) showed no preferable accumulation. We then functionalize the microparticles with glycoprotein VI (GPVI), the main platelet receptor for collagen under low-medium shear, and study their targeting in an in vitro reconstructed patient-specific aneurysm that contained a disrupted endothelium at the cavity. Results in this model showed that GPVI microparticles localize at the injured aneurysm an order of magnitude (>9 folds) more than control particles. Finally, effective targeting to aneurysm sites was also demonstrated in an in vivo rabbit aneurysm model with a disrupted endothelium. Altogether, the presented biophysical strategy for targeted delivery may offer new treatment opportunities for cerebral aneurysms.

Indexed as

aneurysm targetingcerebral aneurysmglycoprotein VI (GPVI) coatingparticle carriersvascular models

Identifiers

PMID35079628
PMCPMC8780020
OpenAlexW3193525557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.